FibroBiologics Inc (FBLG)
2.60
+0.19
(+7.88%)
USD |
NASDAQ |
Nov 22, 16:00
2.59
-0.01
(-0.38%)
After-Hours: 20:00
FibroBiologics Enterprise Value: 82.40M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 82.40M |
| November 21, 2024 | 75.82M |
| November 20, 2024 | 69.92M |
| November 19, 2024 | 74.78M |
| November 18, 2024 | 79.11M |
| November 15, 2024 | 81.71M |
| November 14, 2024 | 89.68M |
| November 13, 2024 | 99.04M |
| November 12, 2024 | 102.16M |
| November 11, 2024 | 111.86M |
| November 08, 2024 | 118.46M |
| November 07, 2024 | 113.38M |
| November 06, 2024 | 113.71M |
| November 05, 2024 | 102.52M |
| November 04, 2024 | 95.40M |
| November 01, 2024 | 100.15M |
| October 31, 2024 | 94.72M |
| October 30, 2024 | 92.35M |
| October 29, 2024 | 85.56M |
| October 28, 2024 | 87.94M |
| October 25, 2024 | 88.95M |
| October 24, 2024 | 89.97M |
| October 23, 2024 | 88.28M |
| October 22, 2024 | 89.97M |
| October 21, 2024 | 95.91M |
| Date | Value |
|---|---|
| October 18, 2024 | 107.27M |
| October 17, 2024 | 104.90M |
| October 16, 2024 | 102.18M |
| October 15, 2024 | 85.56M |
| October 14, 2024 | 83.87M |
| October 11, 2024 | 80.47M |
| October 10, 2024 | 70.98M |
| October 09, 2024 | 79.80M |
| October 08, 2024 | 85.56M |
| October 07, 2024 | 86.24M |
| October 04, 2024 | 88.62M |
| October 03, 2024 | 82.17M |
| October 02, 2024 | 83.19M |
| October 01, 2024 | 90.65M |
| September 30, 2024 | 97.09M |
| September 27, 2024 | 106.79M |
| September 26, 2024 | 105.03M |
| September 25, 2024 | 91.28M |
| September 24, 2024 | 97.27M |
| September 23, 2024 | 91.63M |
| September 20, 2024 | 110.67M |
| September 19, 2024 | 105.73M |
| September 18, 2024 | 108.55M |
| September 17, 2024 | 109.61M |
| September 16, 2024 | 108.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.34M
Minimum
Aug 16 2024
936.36M
Maximum
Jan 31 2024
220.32M
Average
173.98M
Median
Jul 29 2024
Enterprise Value Benchmarks
| Charles River Laboratories International Inc | 12.17B |
| CEL-SCI Corp | 36.25M |
| AIM ImmunoTech Inc | 8.915M |
| IGC Pharma Inc | 26.16M |
| NovaBay Pharmaceuticals Inc | 2.608M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.50M |
| Total Expenses (Quarterly) | 3.352M |
| EPS Diluted (Quarterly) | -0.01 |
| Earnings Yield | -21.12% |